This Article  • Full text  • PDF  • eFigures and eTables  • CME Course for This Article  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Macular Degeneration  • Ocular Imaging  • Randomized Controlled Trial  • Prognosis/ Outcomes  • Articles for Residents  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Clinical Trial

Neil M. Bressler, MD; Tom S. Chang, MD; Jennifer T. Fine, ScD; Chantal M. Dolan, PhD; James Ward, PhD; for the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group

Arch Ophthalmol. 2009;127(1):13-21.

Objective  To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT).

Design  Multicenter, double-masked, phase 3 trial (ANCHOR). Participants were randomized in a 1:1:1 ratio to receive 0.3 or 0.5 mg of intravitreal ranibizumab plus sham verteporfin or sham injections plus active verteporfin monthly. The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered at baseline and 1, 2, 3, 6, 9, 12, 18, and 24 months.

Main Outcome Measure  Mean change from baseline in NEI VFQ-25 scores at 12 months.

Results  At 12 months, patients treated with ranibizumab (0.3 mg [n = 137] or 0.5 mg [n = 139]) had mean improvements in NEI VFQ-25 composite scores of 5.9 (95% confidence interval [CI], 3.6 to 8.3) and 8.1 (95% CI, 5.3 to 10.8) points, respectively; patients treated with PDT (n = 142) had a mean improvement of 2.2 points (95% CI, –0.3 to 4.7; vs 0.5 mg of ranibizumab, P < .001; vs 0.3 mg of ranibizumab, P = .003). At each dose through 24 months, patients treated with ranibizumab were more likely to improve in most subscales, including the prespecified subscales (near activities, distance activities, and vision-specific dependency).

Conclusions  Patients treated with ranibizumab were more likely to report clinically meaningful improvements in visual function through 24 months compared with those treated with verteporfin PDT.

Application to Clinical Practice  Ranibizumab treatment in neovascular age-related macular degeneration can improve patient-reported visual function.

Trial Registration  clinicaltrials.gov Identifier: NCT00061594

Author Affiliations: Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland (Dr Bressler); Retina Institute of California, Pasadena (Dr Chang); and Genentech Inc, South San Francisco, California (Drs Fine, Dolan, and Ward).
Group Information: A list of the ANCHOR Research Group members who contributed data for the patients enrolled in this clinical trial was published in N Engl J Med. 2006;355(14):1432-1444.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
Mitchell et al.
Br J Ophthalmol 2010;94:2-13.
ABSTRACT | FULL TEXT  

Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials
Suner et al.
IOVS 2009;50:3629-3635.
ABSTRACT | FULL TEXT